We herein aimed to ascertain whether the ANRIL and ANRIL transcript variants were involved in the manifestation of CAD susceptibility and where ANRIL transcripts are associated with the 9p21.3 CAD risk in the Tanzanian patients. This evidence concerns the gene CDKN2B-AS1 and coronary artery disorder.